BG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bunge Global Ltd (BG) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite positive technical indicators and bullish analyst ratings, the company's financial health, including high leverage and declining net income, coupled with underperformance in its Viterra acquisition, raises concerns. Additionally, recent news highlights significant challenges in its operations. Holding off on investing until the company demonstrates improved financial stability and operational performance is advisable.
The technical indicators for BG are moderately positive. The MACD is above zero and expanding, indicating bullish momentum. The RSI is neutral at 63.615, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above the pivot point of 122.87, with resistance levels at 127.366 and 130.144, and support levels at 118.374 and 115.596.
Analysts have consistently raised price targets, with most maintaining Buy or Overweight ratings.
The agricultural products industry is improving, and biofuels mandates are expected to drive demand.
Bunge's Investor Day highlighted potential midcycle EPS growth and margin-enhancing opportunities.
Recent news highlights a $1.6 billion cash flow deficit and a high net debt to EBITDA ratio of 5.7x, indicating financial instability.
The Viterra acquisition has underperformed, with EBITDA projections missing by 24% and revenue declining by 16.7%.
Challenges in the oilseeds business due to changing consumer demands and the impact of GLP-1 weight loss drugs.
In Q4 2025, revenue increased by 75.47% YoY to $23.76 billion, but net income dropped by 84.22% YoY to $95 million. EPS fell by 88.76% YoY to $0.49, and gross margin declined by 43.71% YoY to 4.25%. These figures indicate significant profitability challenges despite revenue growth.
Analysts are bullish on BG, with multiple firms raising price targets to a range of $130-$145. Key reasons include an improving agricultural products environment, biofuels demand, and confidence in Bunge's multi-year earnings trajectory. However, some analysts have noted concerns about biofuel policy uncertainty and the underperformance of the Viterra acquisition.
